Biodesix, Inc. has announced a partnership with the Association of Pulmonary Advanced Practice Providers (APAPP) to develop educational programs for healthcare providers focusing on lung health. This collaboration aims to introduce new resources on innovative lung nodule risk assessment and cancer treatment decision support testing, utilizing Biodesix's Nodify Lung® and IQLung® blood-based tests. These programs are designed to empower providers in diverse care settings, promoting earlier detection and diagnosis of lung cancer. With lung cancer being the deadliest among cancers, this initiative seeks to improve patient care by providing access to diagnostic options that facilitate timely diagnosis and personalized treatment decisions.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。